Key Findings from DETECT-HF
The DETECT-HF pivotal validation study, presented at the American Heart Association (AHA) Scientific Sessions 2026, demonstrated that the HearO system predicted more than 70% of heart failure events. On average, these events were identified 24.6 days before occurrence. The blinded, multicenter study involved 563 patients across 46 sites, primarily in the U.S. and international academic medical centers. Results showed no device-related adverse events and a rate of unexplained alerts at 2.65 per patient per year, meeting the study’s goal of fewer than three.
Technical Implementation
HearO utilizes speech signal processing and AI to detect changes in the voice associated with fluid accumulation in the lungs. The system creates a patient-specific voice model using short daily recordings captured on standard Android and iOS smartphones, requiring no additional hardware. The patented technology is language-independent; participants in the study spoke English, Spanish, Hebrew, Russian, and Arabic. When the AI detects deterioration, it notifies the care team via a secure web-based portal.
Background and Clinical Context
Heart failure affects approximately 7.7 million adults in the U.S., with annual national costs exceeding $40 billion. While clinicians can often hear voice changes once a patient is decompensated at the hospital, remote monitoring for fluid buildup has remained a challenge. Conventional methods, such as daily weight measurements, often suffer from poor adherence, while advanced alternatives may require invasive procedures. HearO’s ease of use resulted in patients completing 85% of scheduled recordings, with mean usability ratings between 4.7 and 4.9 out of 5.
Regulatory Status and Roadmap
The HearO system has received Breakthrough Device designation from the U.S. FDA, is CE marked in Europe, and is approved in Israel. Cordio Medical intends to use the DETECT-HF results to pursue FDA marketing authorization through the De Novo pathway. The company plans a U.S. launch in 2027, though the system is currently limited to investigational use in the U.S.
Source: https://finance.yahoo.com/healthcare/articles/pivotal-study-validates-cordio-medicals-133000053.html
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



